Connect Biopharma Holdings (Connect Biopharma Holdings) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Connect Biopharma Holdings's EBITDA for the six months ended in Dec. 2023 was $-29.71 Mil. Connect Biopharma Holdings's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Connect Biopharma Holdings's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Connect Biopharma Holdings EBITDA Margin % Historical Data

The historical data trend for Connect Biopharma Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings EBITDA Margin % Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Connect Biopharma Holdings's EBITDA Margin %

For the Biotechnology subindustry, Connect Biopharma Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's EBITDA Margin % falls into.

Connect Biopharma Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Connect Biopharma Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-58.372	/	0
	=	%

Connect Biopharma Holdings's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-29.707	/	0
	=	%

Connect Biopharma Holdings (NAS:CNTB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Connect Biopharma Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.